Company
LON:IXI
IXICO is no ordinary Imaging Contract Research Organisation (iCRO). By unlocking valuable insights into drug safety and efficacy, IXICO has built a highly respected global reputation and a 20-year track record as an end-to-end iCRO. IXICO addresses the complex biomarker challenges associated with neurodegenerative conditions, expertly managing and analysing neuroimaging clinical trials in areas such as Alzheimer’s, Parkinson’s, Huntington's and other rare diseases.
263 stories · page 5 of 14
In its results for the six months ended March 31, the neuroscience-focused data analytics firm reported earnings of £0.9mln, up from £0.7mln a year ago, while revenues rose to £4.9mln to £4.6mln
The study is worth in excess of £1mln over five years
The company received the new work from an existing client
“The focus on commercialisation and profitability by CEO Giulio Cerroni continues to deliver meaningful growth for the business and investors, and we would anticipate further positive momentum going forward”
The new Phase II acute ischemic stroke trial will be conducted across 50 sites in North America and Europe
Company has a healthy order book and strong cash position
The strong book to bill ratio for the period reflects the resilience of the operating model , the company said
The company’s digital platform and Artificial Intelligence (AI) software manages and helps interpret images from MRI (magnetic resonance imaging) and PRT (positron emission tomography) scanners
The decision followed an independent committee review of the potential benefit/risk profile
IXICO continues to scale up in the highly regulated clinical trials environment
It will provide 'advanced solutions’ involving structural magnetic resonance imaging
Alzheimer’s affects an estimated 50mln people worldwide with devastating mental and physical consequences
The company will provide operational services and advanced AI neuroimaging expertise
The contract win was included in management's expectations of performance for the current financial year but adds to the company's strong order book
The neuroimaging data analytics firm also reported a 36% increase in its contracted order book to a record level of £21.7mln
The award recognises the company's long track record of research in the area of Huntington's disease
The group will carry out work on a phase I study, it has also signed an expansion deal for a phase II clinical assessment, and it will deploy its expertise on an open-label extension phase III trial
The contracts include retrospective analysis of data sets for three Natural History Studies in Huntington's disease with a new large pharma customer and a multicentre, open-label Phase II study in Huntington's disease with an existing large
In a trading update, the group said earnings before interest, tax, depreciation, and amortisation should at least meet market expectations of £1.1mln (2019: £0.5mln)
Dr Robin Wolz, senior vice president for science and innovation at IXICO, said: "This collaboration will help to accelerate the quest for new treatments for multiple system atrophy by bringing together some of the leading researchers in the
